URB597 (KDS-4103) is an orally bioavailable fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4.6 nM, showing no inhibitory activity against other cannabinoid-related targets; it is in Phase 1 clinical development. It exhibits anti-inflammatory effects by reducing LPS-induced expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS/NOS2) in primary rat microglial cells, thereby decreasing the release of inflammatory mediators prostaglandin E2 (PGE2) and nitric oxide (NO). URB597 activates TRPA1 channels, inducing Ca²⁺ influx in HEK293-F cells transiently expressing human or rat TRPA1 and in rat dorsal root ganglion (DRG) neurons. In vivo, it inhibits [³H]anandamide hydrolysis in rat brain membranes, elevates brain levels of anandamide, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA), enhances anandamide-induced hypothermia, and produces analgesic effects in inflammatory pain models via cannabinoid CB1 and CB2 receptor-mediated mechanisms, reducing allodynia and hyperalgesia. Chronic administration (0.3 mg/kg/day, i.p. for 5 weeks) alleviates chronic mild stress-induced impairments in body weight gain and glucose uptake. Additionally, URB597 reverses depressive-like symptoms induced by adolescent THC exposure in female rats.